ACRS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.5M
-9.1%
1.6M
-18.4%
2.0M
+54.1%
1.3M
-60.7%
3.3M
Cost of Revenue
189.0K
-13.3%
218.0K
-44.8%
395.0K
-25.8%
532.0K
-1.1%
538.0K
Gross Profit
1.3M
-8.4%
1.4M
-11.9%
1.6M
+109.8%
763.0K
-72.4%
2.8M
Operating Expenses
22.6M
-11.7%
25.6M
+7.8%
23.8M
+1.3%
23.5M
+18.0%
19.9M
R&D
16.1M
-11.1%
18.1M
+15.4%
15.7M
-5.6%
16.6M
+27.3%
13.0M
SG&A
6.0M
-0.2%
6.0M
-10.3%
6.7M
+20.9%
5.6M
+14.5%
4.9M
Operating Income
-21344000
+11.9%
-24238000
-9.2%
-22192000
+2.4%
-22734000
-32.6%
-17149000
EBITDA
-21244000
+12.0%
-24131000
-9.2%
-22090000
+0.6%
-22232000
-30.5%
-17039000
Net Income
-18510000
+13.9%
-21505000
-8.5%
-19824000
-0.1%
-19795000
-35.5%
-14614000
EPS (Basic)
$-0.12
+20.0%
$-0.15
+0.0%
$-0.15
+6.3%
$-0.16
-33.3%
$-0.12
EPS (Diluted)
$-0.12
+20.0%
$-0.15
+0.0%
$-0.15
+6.3%
$-0.16
-33.3%
$-0.12
Shares (Diluted)
149.4M
+4.7%
142.7M
+10.8%
128.8M
+5.0%
122.7M
+0.0%
122.6M
Aclaris Therapeutics (ACRS) — Financials